On the issue of the new edition of the international classification of retinopathy of prematurity. Part 2

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Retinopathy of prematurity (ROP) is the leading cause of visual disability from early childhood. Foreign researchers and clinicians are focused on studying a new pharmacological method of treatment of active RN using anti-VEGF drugs, which was a reason that prompted updates in the International Classification of Retinopathy of Prematurity (ICROP) in 2021. The second part of the article presents new terms recommended by the Committee for the ICROP: “regression,” which refers to the involution and resolution of the disease, and “reactivation,” which denotes a recurrence of signs in the acute phase. Notably, the latest edition of the ICROP requires a deep understanding and accurate application by domestic specialists treating ROP. This contributes to the standardization of therapeutic and diagnostic processes, therefore, improving the quality of ROP treatment in Russia.

Full Text

Restricted Access

About the authors

Elvira I. Saidasheva

North-Western State Medical University named after I.I. Mechnikov; Children’s city multidisciplinary clinical specialized center for high medical technologies

Author for correspondence.
Email: esaidasheva@mail.ru
ORCID iD: 0000-0003-4012-7324
SPIN-code: 7800-3264

MD, Dr. Sci. (Medicine)

Russian Federation, Saint Petersburg; Saint Petersburg

References

  1. Chiang MF, Quinn GE, Fielder AR, et al. International Classification of Retinopathy of Prematurity, 3rd edition. Ophthalmology. 2021;128(10):51–68. doi.org/10.1016/j.ophtha.2021.05.031
  2. Saidasheva EI. The new edition of the international classification of retinopathy of premature. Part 1. Russian Pediatric Ophthalmology. 2022;17(1):33–37. doi: 10.17816/rpoj100683
  3. Saidasheva EI, Gorelik YV, Kovshov FV, et al. Experience in treating posterior aggressive retinopathy of prematurity by intravitreal administration of ranibizumab. Russian National Ophthalmological Forum. 2023;2:417–419. EDN: ZMRJYH
  4. Shah PK, Narendran V, Tawansy KA, et al. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol. 2007;55(1):75–76. doi: 10.4103/0301-4738.29505
  5. Mintz-Hittner HA, Kennedy KA, Chuang AZ. BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603–615.
  6. Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394(10208):1551–1559. doi: 10.1016/S0140-6736(19)31344-3
  7. Stahl A, Sukgen EA, Wu WC, et al. FIREFLEYE Study Group. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial. JAMA. 2022;328(4):348–359. doi: 10.1001/jama.2022.10564
  8. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012;32(3):434–457. doi: 10.1097/IAE.0B013E31822C290F

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. The fundus of the right eye of a patient with a gestational age of 26 weeks: a — posterior aggressive retinopathy of prematurity; b — regression after intravitreal anti-VEGF injection at 33 weeks of postconceptual age; c — reactivated stage 3 plus-retinopathy of prematurity at 40 weeks of postconceptual age; d — induced regression after laser coagulation of the retina.

Download (123KB)

Copyright (c) 2024 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86503 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80630 от 15.03.2021 г
.